Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
JAMA Network Open|October 12, 2021
Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical TrialTimo Vesikari, Adam Finn, Pierre van Damme, et al.
Wiener Klinische Wochenschrift|August 11, 2021
Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trialPeter G Kremsner, Philipp Mann, Arne Kroidl, et al.
The Journal of Infectious Diseases|June 10, 2024
Safety and Immunogenicity of a 4-Component Generalized Modules for Membrane Antigens Shigella Vaccine in Healthy European Adults: Randomized, Phase 1/2 StudyIsabel Leroux-Roels, Cathy Maes, Francesca Mancini, et al.
The Lancet. Infectious Diseases|July 28, 2024
Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trialIsabel Leroux-Roels, Chittappen Kandiyil Prajeeth, Amare Aregay, et al.
The New England Journal of Medicine|January 13, 2021
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 VaccineJerald Sadoff, Mathieu Le Gars, Georgi Shukarev, et al.
Influenza and Other Respiratory Viruses|March 9, 2025
Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024Liliana Antunes, Madelyn Rojas-Castro, Marcos Lozano, et al.
The Lancet. Infectious Diseases|November 26, 2021
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trialPeter G Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana-Arri, et al.
Pageof 8